One- and Two-Dose Vaccinations With Modified Vaccinia Ankara-Bavarian Nordic Induce Durable B-Cell Memory Responses Comparable to Replicating Smallpox Vaccines
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
One- and Two-Dose Vaccinations With Modified Vaccinia Ankara-Bavarian Nordic Induce Durable B-Cell Memory Responses Comparable to Replicating Smallpox Vaccines
Authors
Keywords
-
Journal
JOURNAL OF INFECTIOUS DISEASES
Volume -, Issue -, Pages -
Publisher
Oxford University Press (OUP)
Online
2022-11-17
DOI
10.1093/infdis/jiac455
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The changing epidemiology of human monkeypox—A potential threat? A systematic review
- (2022) Eveline M. Bunge et al. PLoS Neglected Tropical Diseases
- Estimated incubation period for monkeypox cases confirmed in the Netherlands, May 2022
- (2022) Fuminari Miura et al. Eurosurveillance
- Monkeypox Virus Infection in Humans across 16 Countries — April–June 2022
- (2022) John P. Thornhill et al. NEW ENGLAND JOURNAL OF MEDICINE
- A randomized phase II trial to compare safety and immunogenicity of the MVA-BN smallpox vaccine at various doses in adults with a history of AIDS
- (2020) Edgar Turner Overton et al. VACCINE
- Persistence of HB sAg‐specific antibodies and immune memory two to three decades after hepatitis B vaccination in adults
- (2019) Pierre Van Damme et al. JOURNAL OF VIRAL HEPATITIS
- Phase 3 Efficacy Trial of Modified Vaccinia Ankara as a Vaccine against Smallpox
- (2019) Phillip R. Pittman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immunogenicity and safety of three consecutive production lots of the non replicating smallpox vaccine MVA: A randomised, double blind, placebo controlled phase III trial
- (2018) Edgar Turner Overton et al. PLoS One
- Emergence of Monkeypox — West and Central Africa, 1970–2017
- (2018) Kara N. Durski et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- Two cases of monkeypox imported to the United Kingdom, September 2018
- (2018) Aisling Vaughan et al. Eurosurveillance
- Non-Neutralizing Antibodies Directed against HIV and Their Functions
- (2017) Luzia M. Mayr et al. Frontiers in Immunology
- Both Neutralizing and Non-Neutralizing Human H7N9 Influenza Vaccine-Induced Monoclonal Antibodies Confer Protection
- (2016) Carole J. Henry Dunand et al. Cell Host & Microbe
- British HIV Association Guidelines on the Use of Vaccines in HIV-Positive Adults 2015
- (2016) Anna Maria Geretti et al. HIV MEDICINE
- Use of Vaccinia Virus Smallpox Vaccine in Laboratory and Health Care Personnel at Risk for Occupational Exposure to Orthopoxviruses — Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2015
- (2016) Brett W. Petersen et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- A Randomized, Double-Blind, Placebo-Controlled Phase II Trial Investigating the Safety and Immunogenicity of Modified Vaccinia Ankara Smallpox Vaccine (MVA-BN®) in 56-80-Year-Old Subjects
- (2016) Richard N. Greenberg et al. PLoS One
- Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-naïve subjects
- (2015) Sharon E. Frey et al. VACCINE
- Safety and Immunogenicity of Modified Vaccinia Ankara-Bavarian Nordic Smallpox Vaccine in Vaccinia-Naive and Experienced Human Immunodeficiency Virus-Infected Individuals: An Open-Label, Controlled Clinical Phase II Trial
- (2015) E. T. Overton et al. Open Forum Infectious Diseases
- Cardiac Safety of Modified Vaccinia Ankara for Vaccination against Smallpox in a Young, Healthy Study Population
- (2015) Eva-Maria Zitzmann-Roth et al. PLoS One
- A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA Smallpox Vaccine (IMVAMUNE) in 18–40 Year Old Subjects with Diagnosed Atopic Dermatitis
- (2015) Richard N Greenberg et al. PLoS One
- Executive Summary: 2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host
- (2014) Lorry G. Rubin et al. CLINICAL INFECTIOUS DISEASES
- Safety and immunogenicity of modified vaccinia Ankara as a smallpox vaccine in people with atopic dermatitis
- (2014) Frank von Sonnenburg et al. VACCINE
- Phase II randomized, double-blinded comparison of a single high dose (5×108 TCID50) of modified vaccinia Ankara compared to a standard dose (1×108 TCID50) in healthy vaccinia-naïve individuals
- (2014) Sharon E. Frey et al. VACCINE
- The persistence of anti-HBs antibody and anamnestic response 20 years after primary vaccination with recombinant hepatitis B vaccine at infancy
- (2014) Masoomeh Bagheri-Jamebozorgi et al. Human Vaccines & Immunotherapeutics
- Safety and Immunogenicity of Modified Vaccinia Ankara in Hematopoietic Stem Cell Transplant Recipients: A Randomized, Controlled Trial
- (2013) Stephen R. Walsh et al. JOURNAL OF INFECTIOUS DISEASES
- Safety and immunogenicity of IMVAMUNE® smallpox vaccine using different strategies for a post event scenario
- (2013) Sharon E. Frey et al. VACCINE
- Safety, Immunogenicity, and Surrogate Markers of Clinical Efficacy for Modified Vaccinia Ankara as a Smallpox Vaccine in HIV-Infected Subjects
- (2012) R. N. Greenberg et al. JOURNAL OF INFECTIOUS DISEASES
- Countermeasures and vaccination against terrorism using smallpox: pre-event and post-event smallpox vaccination and its contraindications
- (2010) Hajime Sato Environmental Health and Preventive Medicine
- Evaluation of smallpox vaccines using variola neutralization
- (2009) I. K. Damon et al. JOURNAL OF GENERAL VIROLOGY
- Modified vaccinia Ankara strains with identical coding sequences actually represent complex mixtures of viruses that determine the biological properties of each strain
- (2009) Mark Suter et al. VACCINE
- A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE®
- (2009) Alfred von Krempelhuber et al. VACCINE
- Vaccines: Correlates of Vaccine‐Induced Immunity
- (2008) Stanley A. Plotkin CLINICAL INFECTIOUS DISEASES
- Determination of the appropriate quarantine period following smallpox exposure: An objective approach using the incubation period distribution
- (2008) Hiroshi Nishiura INTERNATIONAL JOURNAL OF HYGIENE AND ENVIRONMENTAL HEALTH
- Long‐Term Persistence of Mumps Antibody after Receipt of 2 Measles‐Mumps‐Rubella (MMR) Vaccinations and Antibody Response after a Third MMR Vaccination among a University Population
- (2008) Anand A. Date et al. JOURNAL OF INFECTIOUS DISEASES
- Rapid protection in a monkeypox model by a single injection of a replication-deficient vaccinia virus
- (2008) P. L. Earl et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now